Benzinga

Benzinga

Benzinga

martes, agosto 25

Immunovant Inc

IMVTNASDAQ
Trade with Public
Trade with Public
$43.32
-1.05-2.37%
al cierre: Aug 24, 5:00 PM EST
$43.80
0.481.11%
After hour: 5:23 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Immunovant Financials

Immunovant (IMVT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the
Benzinga Newsdesk

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
Avi Kapoor

Immunovant Stock Surges Despite Disappointing Earnings Miss

Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
Evette Mitkov

Earnings Scheduled For May 20, 2026

Benzinga Insights

PRO
Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of $(0.64) per share from the
Benzinga Newsdesk

PRO
Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved